Heart peptides and HFpEF (heart failure with preserved ejection fraction) DOI Creative Commons
Kazuhiro Takahashi

Peptides, Год журнала: 2022, Номер 157, С. 170866 - 170866

Опубликована: Сен. 5, 2022

Язык: Английский

Artificial intelligence and heart failure: A state‐of‐the‐art review DOI
Muhammad Shahzeb Khan, Muhammad Sameer Arshad, Stephen J. Greene

и другие.

European Journal of Heart Failure, Год журнала: 2023, Номер 25(9), С. 1507 - 1525

Опубликована: Авг. 10, 2023

Язык: Английский

Процитировано

36

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT DOI
João Pedro Ferreira, Brian Claggett, Jiankang Liu

и другие.

International Journal of Cardiology, Год журнала: 2024, Номер 402, С. 131818 - 131818

Опубликована: Фев. 1, 2024

Язык: Английский

Процитировано

13

Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure DOI

Archanna Radakrishnan,

Shashank Agrawal, Neha Singh

и другие.

Journal of Cardiac Failure, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

2

Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype DOI Creative Commons
Yijia Li, Hajime Kubo, Daohai Yu

и другие.

AJP Heart and Circulatory Physiology, Год журнала: 2023, Номер 324(4), С. H443 - H460

Опубликована: Фев. 10, 2023

Heart failure (HF) with preserved ejection fraction (HFpEF) is defined as HF an (EF) ≥ 50% and elevated cardiac diastolic filling pressures. The underlying causes of HFpEF are multifactorial not well-defined. A transgenic mouse low levels cardiomyocyte (CM)-specific inducible Cavβ2a expression (β2a-Tg mice) showed increased cytosolic CM Ca

Язык: Английский

Процитировано

14

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction DOI Creative Commons

Zifeng Yang,

Ruifeng Tian, Xiao‐Jing Zhang

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2023, Номер 9

Опубликована: Янв. 12, 2023

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become most common chronic main form of (HF), respectively. NAFLD is closely associated HFpEF by sharing risk factors and/or boosting systemic inflammation, releasing other secretory factors, having an expansion epicardial adipose tissue (EAT). Therefore, treatments may also affect development prognosis HFpEF. However, no specific drugs for been approved Food Drug Administration (FDA) some non-specific are applied in clinic. Currently, can be divided into non-pharmacological pharmacological treatments. Non-pharmacological mainly include dietary intervention, weight loss exercise, caloric restriction, bariatric surgery. Pharmacological administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin. This review will focus on analyzing how these

Язык: Английский

Процитировано

9

Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure DOI Creative Commons

Archanna Radakrishnan,

Saloni Agrawal,

Nausheen Singh

и другие.

American Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown, С. 100928 - 100928

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0

Maintained sympathetic reactivity but blunted pressor response to static handgrip exercise in heart failure with preserved ejection fraction DOI
Takuro Washio, Ryosuke Takeda, Sarah L. Hissen

и другие.

Clinical Autonomic Research, Год журнала: 2025, Номер unknown

Опубликована: Фев. 26, 2025

Язык: Английский

Процитировано

0

Molecular Insights into Oxidative-Stress-Mediated Cardiomyopathy and Potential Therapeutic Strategies DOI Creative Commons
Zhengfeng Xiong, Yuanpeng Liao, Z. Zhang

и другие.

Biomolecules, Год журнала: 2025, Номер 15(5), С. 670 - 670

Опубликована: Май 6, 2025

Cardiomyopathies comprise a heterogeneous group of cardiac disorders characterized by structural and functional abnormalities in the absence significant coronary artery disease, hypertension, valvular or congenital defects. Major subtypes include hypertrophic, dilated, arrhythmogenic, stress-induced cardiomyopathies. Oxidative stress (OS), resulting from an imbalance between reactive oxygen species (ROS) production antioxidant defenses, has emerged as key contributor to pathogenesis these conditions. ROS-mediated injury drives inflammation, protease activation, mitochondrial dysfunction, cardiomyocyte damage, thereby promoting remodeling decline. Although numerous studies implicate OS cardiomyopathy progression, precise molecular mechanisms remain incompletely defined. This review provides updated synthesis current findings on OS-related signaling pathways across subtypes, emphasizing emerging therapeutic targets within redox-regulatory networks. A deeper understanding may guide development targeted strategies improve clinical outcomes affected patients.

Язык: Английский

Процитировано

0

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis DOI Creative Commons
Wanqian Yu, Fan Luo,

Jingan Rao

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12

Опубликована: Май 27, 2025

Background Finerenone has been shown to improve outcomes in patients with heart failure (HF), encompassing those reduced (HFrEF), mildly (HFmrEF), or preserved ejection fraction (HFpEF). However, its clinical use is accompanied by notable adverse effects. This study aimed evaluate the relative risks of events associated finerenone across HF phenotypes. Methods A systematic search PubMed, Embase, and Web Science identified six randomized controlled trials involving 8,527 patients. The analysis considered hyperkalemia, hypotension, treatment-emergent (TEAEs), serious (TESAEs), treatment discontinuation due events. Results significantly increased risk hyperkalemia (RR = 2.07, 95% CI 1.77-2.44, P < 0.00001) hypotension 1.49, 1.31-1.68, compared placebo, irrespective phenotype. No significant differences were observed between placebo terms TEAEs, TESAEs, when analyzing overall population. Compared eplerenone, was a lower TEAEs 0.93, CI: 0.89-0.98) TESAEs 0.74, 0.66-0.84), similar rates. Additionally, one included suggested that may have 0.64, 0.56-0.74), 0.37, 0.25-0.54) 0.41, 0.21-0.79) spironolactone, rates 0.61, 0.29-1.30) HFrEF. Conclusion (10-25 mg) showed safety profile no discontinuation. fewer comparable Moreover, HFrEF, offer discontinuation, than hypotension.

Язык: Английский

Процитировано

0

Heart Failure in Menopause: Treatment and New Approaches DOI Open Access
Jaqueline da Silva, Tadeu L. Montagnoli,

Mauro Paes Leme de Sá

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(23), С. 15140 - 15140

Опубликована: Дек. 1, 2022

Aging is an important risk factor for the development of heart failure (HF) and half patients with HF have preserved ejection fraction (HFpEF) which more common in elderly women. In general, sex differences that lead to discrepancies factors cardiovascular disease (CVD) been attributed reduced level circulating estrogen during menopause. Estrogen receptors adaptively modulate fibrotic, apoptotic, inflammatory processes calcium homeostasis, are directly involved HFpEF. Therefore, menopause, depletion reduces cardioprotection. Preclinical menopause models demonstrated several signaling pathways organ systems closely HFpEF, including dysregulation renin-angiotensin system (RAS), chronic process alteration sympathetic nervous system. Thus, this review explores thealterations observed condition HFpEF induced by therapeutic targets potential interfere progress.

Язык: Английский

Процитировано

14